KALV News
Archived Headlines
- Carbylan Therapeutics postpones $75 million IPO 02/17/15
- Week ahead: 12 IPOs feature health care, holdovers and a $500 million health tech IPO 02/09/15
- Week ahead: IPO market set for another surge in the health care sector with 10 IPOs 02/02/15
- Osteoarthritis pain biotech Carbylan Therapeutics sets terms for $75 million IPO 01/23/15
- Osteoarthritis pain biotech Carbylan Therapeutics files for a $86 million IPO 12/29/14
No pain, more gains: Axsome Therapeutics files for a $58 million IPO
Axsome Therapeutics, which is developing novel therapies for pain and CNS disorders utilizing the 505(b)(2) pathway, filed on Tuesday with the SEC to raise up to $58 million in an initial public offering. The company cites 2015 IPOs Carbylan Therapeutics...read more
US IPO Weekly Recap: 2 US IPOs feature first Chinese tech offering of 2015
Just two small and delayed IPOs - a Chinese e-commerce company and a biotech - raised $105 million this week as management typically avoids investor roadshows before Easter. The real action in the IPO market came from names like Party City (PRTY), Virtu...read more
Osteoarthritis pain biotech Carbylan Therapeutics prices upsized IPO at $5
Carbylan Therapeutics, which is developing a novel, injectable treatment for osteoarthritis pain in the knee, raised $65 million in an upsized IPO by offering 13 million shares (all primary) at $5. Carbylan originally planned to raise $75 million at a $211...read more
Biotech Carbylan Therapeutics revives IPO, cuts offer price to $5
Carbylan Therapeutics, which is developing a novel, injectable treatment for osteoarthritis pain in the knee, revived terms for its IPO on Monday. The company, which had been looking to raise $75 million by offering 5.8 million shares at a price range of...read more